378 related articles for article (PubMed ID: 26763740)
1. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
2. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
3. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
[TBL] [Abstract][Full Text] [Related]
5. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
[TBL] [Abstract][Full Text] [Related]
6. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
[TBL] [Abstract][Full Text] [Related]
7. CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Liu H; Peng F; Liu Z; Jiang F; Li L; Gao S; Wang G; Song J; Ruan E; Shao Z; Fu R
Int J Oncol; 2017 Feb; 50(2):631-639. PubMed ID: 28035364
[TBL] [Abstract][Full Text] [Related]
8. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
9. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
10. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
[TBL] [Abstract][Full Text] [Related]
12. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
[TBL] [Abstract][Full Text] [Related]
14. CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in Myeloma Bone Disease.
Yan S; Liu H; Liu Z; Peng F; Jiang F; Li L; Fu R
Cancer Med; 2020 Jan; 9(2):737-744. PubMed ID: 31769620
[TBL] [Abstract][Full Text] [Related]
15. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
16. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
[TBL] [Abstract][Full Text] [Related]
17. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
18. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
19. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Zhou F; Meng S; Song H; Claret FX
Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
[TBL] [Abstract][Full Text] [Related]
20. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
